15% OFF YOUR FIRST ORDER · CODE 1stOrder
Research hub

Melanotan II Peptide

Melanotan II Peptide is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH), containing a lactam bridge within its peptide structure.

Melanotan II · α-MSH
Molecular Weight
1024.18 g/mol
Molecular Formula
C₅₀H₆₉N₁₅O₉
CAS Number
121062-08-6
Purity
99.5%
Available nowMelanotan II Peptide · in stock, EU dispatch
Melanotan 2 Nasal Spray
99.5%
Price range: $34.24 through $62.23View
Melanotan 2 Peptide Vial
10mg
Price range: $24.24 through $35.46View
Melanotan 2 Pre Mixed Peptide 10mg
10mg
Price range: $27.46 through $74.15View
01

What Is Melanotan II?

Melanotan II is a melanocortin peptide derived from the α-MSH sequence. It has a seven-residue peptide framework containing Nle, Asp, His, D-Phe, Arg, Trp, and Lys. The peptide is chemically represented as Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂.

Its defining structural feature is an internal lactam linkage formed between the side chains of Asp and Lys. This linkage constrains the peptide into a cyclic conformation. The molecule therefore differs structurally from the native linear α-MSH peptide through both its selected amino-acid substitutions and its intramolecular cyclization.

02

Research Overview Table

Research OverviewCurrent Status
Compound ClassSynthetic cyclic melanocortin peptide
Primary Research TargetMelanocortin receptors (MC1R, MC3R, MC4R, and MC5R)
Published Cell StudiesAvailable
Published Animal StudiesAvailable
Controlled Human Clinical TrialsLimited early-phase clinical studies
Primary Research FieldMelanocortin receptor biology, melanocortin peptide pharmacology, and peptide structure–activity research
Research MaturityPredominantly preclinical
Intended UseLaboratory research only
03

Chemical and Molecular Characteristics

Chemical NameN-Acetyl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysinamide, cyclic (2→7)-peptide
Compound NameMelanotan II Peptide
Compound TypeSynthetic cyclic heptapeptide
Molecular FormulaC₅₀H₆₉N₁₅O₉
Molecular Weight1024.18 g/mol
Purity99.5%
CAS Number121062-08-6
Batch/Lot Number20250912013
Primary Research TargetMelanocortin receptors (MC1R, MC3R, MC4R and MC5R)
Product FormatLyophilized vials, nasal sprays, or pre-mixed injection pen
Physical PresentationSupplied as sterile lyophilized powder or pre-formulated liquid, depending on the selected product format

Melanotan II has a seven-residue cyclic peptide architecture represented as Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. Its structure incorporates norleucine and D-phenylalanine substitutions, with an internal lactam linkage between the Asp and Lys side chains that produces the constrained cyclic configuration.

The compound has a molecular formula of C₅₀H₆₉N₁₅O₉ and a molecular weight of approximately 1024.2 g/mol. PubChem reports 13 hydrogen-bond donors, 11 hydrogen-bond acceptors, 17 rotatable bonds, and a topological polar surface area of 385 Ų. These characteristics reflect its relatively large, nitrogen- and oxygen-rich peptide architecture and distinguish it from smaller non-peptide research compounds.

Certificates:

CoAhttps://saudi-arabia.direct-sarms.com/wp-content/uploads/2026/09/Melanotan-2_COA.pdf
HPLChttps://saudi-arabia.direct-sarms.com/wp-content/uploads/2026/09/Melanotan-2_HPLC.pdf
04

Mechanism of Action Under Investigation

Melanotan II acts as a nonselective agonist at melanocortin receptors, including MC1R, MC3R, MC4R, and MC5R. These receptors are G protein-coupled receptors. Melanotan II binds to the receptor and promotes an active receptor conformation, initiating intracellular G-protein signaling. Its interaction with the melanocortin receptor family reflects the conserved pharmacophore within melanocortin peptides.

The best-characterized signaling pathway involves Gαs-mediated activation of adenylyl cyclase. This increases intracellular cyclic AMP (cAMP), which acts as a second messenger and activates downstream protein kinase A (PKA) signaling. Studies with MC4R have shown that Melanotan II produces a sustained cAMP signal that can persist after researchers remove the peptide from the surrounding medium. Experimental work has also associated this persistent signaling with downstream AMPK signaling.

Researchers study Melanotan II receptor activity with ligand-binding assays and intracellular cAMP measurements. In MC4R studies, researchers have also used time resolved fluorescence assays to track how long the cAMP signal persists after Melanotan II exposure. These methods directly measure receptor binding and the intracellular signaling that follows receptor activation.

05

Scientific Research Context

Melanotan II has a predominantly preclinical evidence base, with most of the literature coming from published in vitro and animal studies. Human research is more limited but includes early clinical studies. The research progressed from early development and characterization of the cyclic peptide to broader preclinical and clinical investigation. Overall, the literature contains a substantial body of experimental research while human evidence remains comparatively limited.

06

Melanotan II Biology and Biological Pathways

01

Primary Biological Function

Melanotan II belongs to the melanocortin system, which includes five receptor subtypes: MC1R, MC2R, MC3R, MC4R, and MC5R. These receptors have distinct tissue distributions and biological functions. MC1R is closely associated with melanocyte biology, while MC3R and MC4R have important roles in central energy regulation. MC5R has a broader distribution across peripheral tissues. Researchers study these receptor systems to define the biological roles associated with different melanocortin receptor subtypes.

02

Relevant Metabolic or Signaling Pathways

Melanocortin receptors participate in several intracellular signaling pathways. The best characterized pathway involves adenylyl cyclase and cyclic AMP (cAMP). Receptor signaling can also involve ERK1/2, PI3K, protein kinase C, calcium-dependent signaling, and interactions with regulatory proteins such as β-arrestins. Researchers examine these pathways to characterize how melanocortin receptors regulate cellular processes and how signaling differs between receptor subtypes.

03

Tissue-Specific Biology

Melanocortin receptors have distinct but overlapping tissue distributions. MC1R is mainly expressed in melanocytes and skin. MC3R and MC4R are widely expressed in the central nervous system. MC5R has a broader distribution, including exocrine glands, adipose tissue, and skeletal muscle. Studies also show that some tissues express more than one melanocortin receptor subtype.

04

Experimental Biomarkers

Studies of Melanotan II have measured intracellular cAMP, p38 phosphorylation, and c-Fos expression as experimental markers of cellular signaling and activity. Researchers have also used LC-MS/MS to measure its concentrations in plasma and brain tissue. These measurements provide direct markers of signaling responses and peptide levels in experimental systems.

05

Laboratory Investigation Methods

Researchers study Melanotan II using receptor-binding assays, cloned receptor systems, and intracellular cAMP assays. Studies have also used time-resolved fluorescence assays to measure changes in cAMP signaling over time. In animal research, immunohistochemistry and c-Fos staining have been used to examine cellular activity, while LC-MS/MS can measure Melanotan II in plasma and brain tissue.

07

Experimental Models Used in Published Research

Published Melanotan II research includes cell-based systems, cloned receptor models, mice, rats, and human participants. These models range from isolated cellular systems to whole-animal and human studies. Their main limitations involve biological complexity, species differences, and the small size of some human studies.

01

Cell-Based Models

Published Melanotan II research includes in vitro studies using B16-F10 melanoma cells. This model provides a controlled cellular setting for studying Melanotan II. Its main limitation is that cultured cells do not reproduce the interactions among tissues, organs and whole-body systems found in an intact organism.

02

Cloned Receptor Models

Published studies have tested Melanotan II in cloned MC3R and MC4R receptor systems. These models isolate individual receptor subtypes and allow direct comparison of receptor activity. However they do not reproduce the full cellular environment or tissue context of native melanocortin receptors.

03

Mouse Models

Published studies have used C57BL/6 mice and genetically modified mice, including models lacking specific melanocortin receptors. These models allow researchers to study Melanotan II in an intact animal and examine receptor-specific biology. However, differences between mouse and human physiology limit how directly researchers can apply findings from these models to humans.

04

Rat Models

Researchers have used Sprague-Dawley and Wistar rats. These models provide an intact mammalian system for experimental research. However, differences between rat and human biology limit how directly researchers can translate findings from these models to humans.

05

Human Studies

Published human research includes controlled studies in healthy volunteers and men with erectile dysfunction. Human studies provide direct information from people but early Melanotan II studies involved small participant groups. This limits the generalizability of the available human evidence.

08

Melanotan II Published Scientific Research

01

Melanotropic and Pigmentation Activity

Published Melanotan II studies have investigated its melanotropic activity and its ability to increase skin pigmentation. Early clinical research specifically evaluated pigmentation after Melanotan II administration in healthy volunteers. Later work continuing to examine its pigmentation-related effects.

02

Penile Erection and Sexual Function

Published studies have investigated Melanotan II in relation to penile erection, erectile responses, and sexual desire. Human studies examined these responses in men with psychogenic and organic erectile dysfunction.

03

Female Sexual Function

The published literature has also investigated Melanotan II in female sexual responses, including sexual desire, genital arousal, and proceptive sexual behavior.

04

Feeding and Energy Regulation

Animal studies have investigated Melanotan II in relation to feeding behavior, food intake, energy balance, and metabolic regulation, including its relationship with neuropeptide Y activity.

05

Melanocortin Receptor Pharmacology

Published research has investigated Melanotan II within melanocortin receptor pharmacology, including receptor activity and the pharmacological properties of melanocortin receptor agonists.

06

Melanoma-Related Research

Published reports have investigated Melanotan II in relation to melanoma. including clinical reports describing melanoma occurring after Melanotan II exposure. These reports represent a separate clinical research area from the controlled pharmacology studies.

09

Limitations of Current Research

01

Evidence Is Predominantly Preclinical

A large part of the Melanotan II literature comes from experimental work rather than large clinical programs. The published record includes laboratory and animal research alongside a smaller human literature. This evidence base supports investigation of specific biological questions but does not provide the breadth normally expected from an established clinical evidence base.

02

Human Clinical Evidence

The available human evidence remains limited in scope and participant numbers. The published clinical studies do not provide enough evidence to establish how consistently the reported effects apply across larger and more diverse human populations.

03

Species Differences

Differences between animal and human biology limit direct translation of preclinical findings. Receptor biology, physiology, and responses to Melanotan II can differ between species, which reduces confidence when extending animal findings to humans.

04

Study Design Limitations

Differences in study design limit direct comparison across the published literature. Variations in study protocols, administration conditions, outcome measures and comparison methods can affect how researchers interpret findings across studies.

05

Independent Replication

The published literature contains a relatively small number of independent human investigations. Limited repetition of the same research questions across separate research groups makes it harder to determine how consistently individual findings can be reproduced.

06

Long-Term Evidence

Long-term human evidence remains limited. The published literature does not provide sufficient prospective evidence to establish what occurs with prolonged Melanotan II exposure or whether findings observed over short periods remain consistent over time.

10

Analytical Documentation

HPLC separates Melanotan II from related substances and supports chromatographic purity assessment. Published analytical work has used LC-UV methods to identify and quantify Melanotan II and its impurities.

LC-MS combines chromatographic separation with mass analysis. Published Melanotan II studies have used LC-MS/MS and LC-HRMS to identify the compound and characterize its molecular composition.

NMR can provide additional structural information when researchers require detailed peptide characterization, although it is not necessary for every routine Melanotan II analysis.

A Certificate of Analysis records quality-control results for a specific preparation, including identity, purity, and analytical testing. Analytical documentation helps verify what a laboratory preparation contains. It verifies identity and quality, not biological performance.

11

Storage and Laboratory Handling

Qualified laboratory personnel should handle Melanotan II from Direct Sarms Saudi Arabia in a suitable laboratory work area. Keep the vial closed when it is not being used and use clean equipment to limit contamination.

Follow the storage conditions listed for the product. The supplied Certificate of Analysis specifies storage at 2–8°C. Keep the material in its original vial and protect it from conditions that could affect its quality.

Laboratory personnel should use appropriate practices when handling the material and keep the work area clean. Melanotan II is intended for laboratory research use only.

12

Frequently asked questions

Melanotan II is a synthetic cyclic heptapeptide and melanocortin peptide analogue. Published research describes it as a synthetic analogue of α-melanocyte-stimulating hormone (α-MSH). Researchers have studied it as a pharmacological tool in melanocortin research rather than as an established therapeutic compound. Its published literature includes pigmentation, sexual-function, feeding, and receptor-pharmacology studies.
13

Why choose us?

Direct SARMs Saudi Arabia is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.

Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.

Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs Saudi Arabia, we aim to make the research supply process simple, clear, and reliable.

Melanotan II Peptide is supplied solely for laboratory research and analytical purposes. It is not intended for human or veterinary use, consumption, diagnosis, treatment, or any clinical application. Information provided on this page is for scientific reference only and should be considered alongside the cited primary literature and relevant analytical documentation.
Available now

Melanotan II Peptide from Direct Sarms Saudi Arabia

Melanotan 2 Nasal Spray
99.5%
Price range: $34.24 through $62.23View
Melanotan 2 Peptide Vial
10mg
Price range: $24.24 through $35.46View
Melanotan 2 Pre Mixed Peptide 10mg
10mg
Price range: $27.46 through $74.15View